Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
2 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
22 Feb 24
8-K
Kymera Therapeutics Announces Proposed Public Offering
5 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
424B5
Prospectus supplement for primary offering
4 Jan 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024
4 Jan 24
8-K
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
22 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Departure of Directors or Certain Officers
27 Feb 23
S-8
Registration of securities for employees
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
23 Feb 23
8-K
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution
10 Jan 23
8-K
Regulation FD Disclosure
14 Dec 22
8-K
Regulation FD Disclosure
14 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
3 Nov 22
8-K
Regulation FD Disclosure
13 Oct 22
424B3
Prospectus supplement
6 Sep 22
8-K
Kymera Announces $150 Million Private Placement Equity Financing
19 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Latest ownership filings
SC 13D
BAKER BROS. ADVISORS LP
1 Apr 24
4
JULIAN BAKER
1 Apr 24
3
Initial statement of insider ownership
1 Apr 24
4
Bruce Booth
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Change in insider ownership
13 Mar 24
4
Bruce Booth
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Jared Gollob
4 Mar 24
4
Jeremy G Chadwick
4 Mar 24
4
Ellen Chiniara
4 Mar 24
4
Nello Mainolfi
4 Mar 24
4
Bruce N. Jacobs
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Jared Gollob
29 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
4
Jeffrey W. Albers
21 Feb 24
144
Notice of proposed sale of securities
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
12 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
12 Feb 24
4
Jared Gollob
9 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
SC 13G/A
Atlas Venture Fund X, L.P.
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
Jeffrey W. Albers
23 Jan 24
144
Notice of proposed sale of securities
23 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24